RV1729 matching placebo 28 day repeat dose

DRUG2 trials

Sponsors

Respivert Ltd

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseHealthy Volunteers

Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD

CompletedNCT02140346

Respivert LtdChronic Obstructive Pulmonary Disease

Start: 2014-08-31End: 2015-07-31Updated: 2015-07-02

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days

CompletedNCT02140320

Respivert LtdAsthma, Healthy Volunteers

Start: 2014-07-31End: 2015-03-31Updated: 2015-04-14